New Study Shows AML Ages Immune Cells, Leading to Poor Treatment Response
Published on
A new study has found that acute myeloid leukemia (AML) ages and exhausts immune cells, impairing their ability to fight off cancer.
Published on
A new study has found that acute myeloid leukemia (AML) ages and exhausts immune cells, impairing their ability to fight off cancer.
Published on
New data on show CAR T-cell therapy leads to durable remission and long-term survival in children and young adults with relapsed or refractory B-ALL.
Published on
CHOP researchers have tested and developed an “off-the-shelf” chimeric antigen receptor T-cell (CART) using base editing.
Published on
More than 250 experts gathered in Philadelphia and virtually to discuss the latest scientific advancements and breakthroughs in pediatric precision medicine oncology.
Published on
In a COG trial, CHOP researchers found adding bortezomib to chemotherapy significantly improved overall survival in children and young adults with newly diagnosed T-cell lymphoblastic lymphoma (T-LL).
Published on
A new study in Nature has documented the longest persistence of CAR T cell therapy to date.
Published on
Aberrant splicing leads to downregulation of CD22 in pediatric B-ALL, rendering malignant cells resistant to the effects of CD22-directed immunotherapies.
Published on
The treatment modifies a domain in the CAR that targets CD19, making it look more human and therefore less likely to be rejected by patients.
Published on
CHOP researchers have found that MN1 overexpression leads to stabilization of the BAF complex, which leads to overproduction of progenitor and stem cells.
Published on
The FDA has approved a treatment that targets ALK mutations in relapsed, refractory ALK-positive anaplastic large cell lymphoma.